AKTX-102 is a first-in-class ADC that combines a novel CEACAM5-targeting antibody construct with Akari’s proprietary PH1 ...
Akari Therapeutics has filed a new US provisional patent covering AKTX-102, its second antibody drug conjugate targeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results